Skip to main
NMRA

NMRA Stock Forecast & Price Target

NMRA Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Neumora Therapeutics is a clinical-stage biopharmaceutical company with a promising pipeline of seven neuroscience programs targeting novel mechanisms of action for a broad range of neuropsychiatric disorders and neurodegenerative diseases. Recent data from their Phase 2 trial for their lead program NMRA-215, a NLRP3 inhibitor, showed potential for use in switch and maintenance settings. Their second program, NMRA-511, a V1aR antagonist for Alzheimer's Disease Agitation, is expected to enter Phase 2 in 1Q27, with encouraging data in the pre-specified NPI-AA ≥4 population suggesting a differentiated safety profile. The company has a strong cash runway into 3Q27 and multiple near-term catalysts, making it an attractive investment opportunity.

Bears say

Neumora Therapeutics is leveraging a precision-medicine approach for CNS diseases, focusing on MDD, BPD, and AD agitation. Despite having seven clinical and preclinical programs in its pipeline, a negative outlook is maintained due to previous failed trials and the limited value currently ascribed to its most advanced product candidate, navacaprant. The upcoming pivotal readout in 2Q26 may bring a momentary boost to the company's valuation, but its long-term success and revenue potential remain uncertain.

NMRA has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neumora Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neumora Therapeutics Inc (NMRA) Forecast

Analysts have given NMRA a Buy based on their latest research and market trends.

According to 7 analysts, NMRA has a Buy consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neumora Therapeutics Inc (NMRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.